Adaptimmune Therapeutics (NASDAQ:ADAP) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of Adaptimmune Therapeutics (NASDAQ:ADAP) in a report published on Saturday. The brokerage issued a buy rating on the biotechnology company’s stock.

ADAP has been the topic of a number of other reports. Scotiabank decreased their price target on Adaptimmune Therapeutics from $3.15 to $1.40 and set a “sector outperform” rating on the stock in a research report on Friday, March 21st. Wells Fargo & Company decreased their target price on Adaptimmune Therapeutics from $2.00 to $1.50 and set an “equal weight” rating on the stock in a report on Friday, March 21st. Finally, Guggenheim cut their price target on Adaptimmune Therapeutics from $3.00 to $1.75 and set a “buy” rating for the company in a report on Wednesday, March 26th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Adaptimmune Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $1.93.

Adaptimmune Therapeutics Stock Down 4.4 %

Shares of NASDAQ ADAP opened at $0.20 on Friday. Adaptimmune Therapeutics has a 52-week low of $0.20 and a 52-week high of $1.55. The company has a debt-to-equity ratio of 0.62, a quick ratio of 3.82 and a current ratio of 3.85. The business has a fifty day moving average of $0.50 and a two-hundred day moving average of $0.66. The stock has a market cap of $50.41 million, a PE ratio of -0.90 and a beta of 2.52.

Adaptimmune Therapeutics (NASDAQ:ADAP) last announced its quarterly earnings results on Monday, March 24th. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.09). The firm had revenue of $3.22 million for the quarter, compared to the consensus estimate of $16.56 million. Adaptimmune Therapeutics had a negative net margin of 25.43% and a negative return on equity of 74.15%. As a group, equities research analysts expect that Adaptimmune Therapeutics will post -0.14 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Adaptimmune Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Invesco Ltd. boosted its holdings in Adaptimmune Therapeutics by 82.0% in the fourth quarter. Invesco Ltd. now owns 63,335 shares of the biotechnology company’s stock valued at $34,000 after acquiring an additional 28,526 shares during the last quarter. Two Sigma Advisers LP boosted its stake in shares of Adaptimmune Therapeutics by 492.0% in the 4th quarter. Two Sigma Advisers LP now owns 70,735 shares of the biotechnology company’s stock valued at $38,000 after purchasing an additional 58,787 shares during the last quarter. Two Sigma Investments LP grew its position in shares of Adaptimmune Therapeutics by 33.5% during the 4th quarter. Two Sigma Investments LP now owns 76,347 shares of the biotechnology company’s stock worth $41,000 after buying an additional 19,146 shares during the period. Virtu Financial LLC raised its stake in shares of Adaptimmune Therapeutics by 21.5% during the fourth quarter. Virtu Financial LLC now owns 122,696 shares of the biotechnology company’s stock worth $66,000 after buying an additional 21,688 shares during the last quarter. Finally, LPL Financial LLC lifted its holdings in Adaptimmune Therapeutics by 106.5% in the fourth quarter. LPL Financial LLC now owns 183,479 shares of the biotechnology company’s stock valued at $99,000 after buying an additional 94,623 shares during the period. Institutional investors own 31.37% of the company’s stock.

About Adaptimmune Therapeutics

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.